Oncoepigenomics: Making histone lysine methylation count

16Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Increasing studies show that methylation of histone lysine residues is implicated in the development and progression of varying disease states such as schizophrenia, diabetes, and multiple human cancers. Targeting the specific enzymes responsible for these processes has fueled global investigation into the understanding and correction of epigenetic pathology. This review aims to assemble a timely account of the current progress against chromatin-modifying histone lysine methyltransferases (KMTs) and demethylases (KDMs) to inform ongoing and future efforts into this promising field. In particular, we report on their role in tumor growth and progression and the development of small molecules that modulate these enzymes. © 2012 Elsevier Masson SAS. All rights reserved.

Cite

CITATION STYLE

APA

Decarlo, D., & Hadden, M. K. (2012, October). Oncoepigenomics: Making histone lysine methylation count. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2012.08.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free